XML 77 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Financial assets and liabilities subject to fair value measurements    
Contingent consideration payable $ 21,417 $ 20,339
Callidus | Clinical and Regulatory Approval Milestones | ATB-200 Pompe Program    
Financial assets and liabilities subject to fair value measurements    
Contingent consideration payable $ 21,417  
Callidus | Clinical and Regulatory Approval Milestones | Discount rate | ATB-200 Pompe Program | Probability weighted discounted cash flow    
Financial assets and liabilities subject to fair value measurements    
Contingent consideration, measurement input 0.102  
Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Minimum    
Financial assets and liabilities subject to fair value measurements    
Contingent consideration, measurement input 0.88  
Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Maximum    
Financial assets and liabilities subject to fair value measurements    
Contingent consideration, measurement input 0.98